Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity [Konjugerat pneumokockvaccin till patienter med antikroppsbrist – en studie for att jamfora antikroppssvar och cellular immunitet]

Trial Profile

Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity [Konjugerat pneumokockvaccin till patienter med antikroppsbrist – en studie for att jamfora antikroppssvar och cellular immunitet]

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms PNEUMOCELL
  • Most Recent Events

    • 11 Apr 2017 Results published in the Vaccine
    • 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 May 2013 Planned end date (Dec 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top